Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBIT: 2021-2025

Historic EBIT for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to -$1.0 billion.

  • Roivant Sciences' EBIT rose 10.38% to -$306.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 127.01%. This contributed to the annual value of -$1.0 billion for FY2025, which is 122.31% down from last year.
  • Latest data reveals that Roivant Sciences reported EBIT of -$1.0 billion as of FY2025, which was down 122.31% from $4.5 billion recorded in FY2024.
  • Over the past 5 years, Roivant Sciences' EBIT peaked at $4.5 billion during FY2024, and registered a low of -$1.4 billion during FY2022.
  • For the 3-year period, Roivant Sciences' EBIT averaged around $862.3 million, with its median value being -$906.8 million (2023).
  • In the last 5 years, Roivant Sciences' EBIT surged by 595.94% in 2024 and then plummeted by 122.31% in 2025.
  • Roivant Sciences' EBIT (Yearly) stood at -$1.1 billion in 2021, then decreased by 26.22% to -$1.4 billion in 2022, then surged by 32.91% to -$906.8 million in 2023, then surged by 595.94% to $4.5 billion in 2024, then slumped by 122.31% to -$1.0 billion in 2025.